摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-methyl-N-(2-morpholinoethyl)nicotinamide | 1221489-83-3

中文名称
——
中文别名
——
英文名称
6-methyl-N-(2-morpholinoethyl)nicotinamide
英文别名
6-methyl-N-(2-morpholin-4-ylethyl)pyridine-3-carboxamide
6-methyl-N-(2-morpholinoethyl)nicotinamide化学式
CAS
1221489-83-3
化学式
C13H19N3O2
mdl
——
分子量
249.313
InChiKey
NXECYPXVEDYKAJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.2
  • 重原子数:
    18
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.54
  • 拓扑面积:
    54.5
  • 氢给体数:
    1
  • 氢受体数:
    4

反应信息

  • 作为产物:
    描述:
    N-(2-氨基乙基)吗啉6-甲基烟酸盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下, 以 二氯甲烷 为溶剂, 以85%的产率得到6-methyl-N-(2-morpholinoethyl)nicotinamide
    参考文献:
    名称:
    Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors
    摘要:
    A series of N-(2-morpholinoethyl)nicotinamide (1-13) and N-(3-morpholinopropyl)nicotinamide derivatives (14-26) have been designed, synthesized and evaluated in vitro for their monoamine oxidase (MAO) A and B inhibitory activity and selectivity. Most of these synthesized compounds proved to be potent, and selective inhibitors of MAO-A rather than of MAO-B. 5-Chloro-6-hydroxy-N-(2-morpholinoethyl)nicotinamide (13) displayed the highest MAO-A inhibitory potency (IC50 = 0.045 mu M) and a good selectivity. 2-Bromo-N-(2-morpholinoethyl)nicotinamide (3) was the most potent MAO-B inhibitor with the IC50 value of 0.32 mu M, but it was not selective. Molecular dockings of compound 13 were performed in order to give structural insights regarding the MAO-A selectivity. (C) 2010 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2009.12.065
点击查看最新优质反应信息

文献信息

  • JANUS KINASE INHIBITOR COMPOUNDS AND METHODS
    申请人:GOODACRE SIMON CHARLES
    公开号:US20100317643A1
    公开(公告)日:2010-12-16
    The invention provides compounds of Formula I, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, B, D, R 1 , R 2 , R 4 and R 5 are defined herein, a pharmaceutical composition that includes a compound of Formula I and methods of use thereof
    这项发明提供了公式I的化合物,其立体异构体或药学上可接受的盐,其中A、B、D、R1、R2、R4和R5在此处被定义,包括公式I化合物的药物组合物以及其使用方法
  • Arylalkylamine Compound and Process for Preparing the Same
    申请人:Miyazaki Hiroshi
    公开号:US20070225296A1
    公开(公告)日:2007-09-27
    The present invention relates to an arylalkylamine compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, a process for preparing the same, and use of the above-mentioned compound as an activating compound (CaSR agonist) of a Ca sensing receptor, a pharmaceutical composition containing the above-mentioned compound as an effective ingredient, etc. The symbols in the formula represent the following meanings: Ar: optionally substituted aryl or optionally substituted heteroaryl here, the cyclic portion of the heteroaryl is bicyclic heterocyclic ring in which 5- to 6-membered monocyclic heterocyclic ring containing 1 or 2 hetero atom(s) and benzene ring are fused; R 1 : a group selected from the group consisting of optionally substituted cyclic hydrocarbon group, and optionally substituted heterocyclic group; n: an integer of 1 to 3; X: single bonding arm, —CH 2 —, —CO—, —(CH 2 ) m —CO—, —CH(R 2 )—CO—, —(CH 2 ) p —Y—(C(R 3 )(R 4 )) q —CO—, —NH—CO— or —N(R 5 )—CO—; in the above-mentioned respective definitions of the X, the bonding arm described at the left end represents a bond with R 1 ; m is an integer of 1 to 3; p is an integer of 0 to 2; q is an integer of 0 to 2; Y: —O— or —SO 2 —; R 2 : phenyl or lower alkyl; R 3 , R 4 : each independently represents hydrogen atom or lower alkyl; R 5 : lower alkyl; provided that the ring portion of the group represented by R 1 is neither naphthylidine nor partially saturated group thereof, and, when X is —CH 2 — or —CO—, R 1 is not naphthyl.
    本发明涉及一种由以下公式[I]表示的芳基烷基胺化合物或其药学上可接受的盐,其制备方法,以及上述化合物作为感受受体的激活化合物(CaSR激动剂),以及含有上述化合物作为有效成分的制药组合物等的用途。公式中的符号表示以下含义:Ar:此处为可选取代的芳基或可选取代的杂环芳基,其中杂环的环部分是一个含有1或2个杂原子的5-至6元单环杂环,与苯环融合;R1:选自可选取代的环烃基团和可选取代的杂环基团的群;n:1至3的整数;X:单键臂、—CH2—、—CO—、—( )m—CO—、—CH(R2)—CO—、—( )p—Y—(C(R3)(R4))q—CO—、—NH—CO—或—N(R5)—CO—;在上述各定义的X中,左端所描述的键臂表示与R1的键;m为1至3的整数;p为0至2的整数;q为0至2的整数;Y:—O—或—SO2—;R2:苯基或低碳烷基;R3、R4:各自独立地表示氢原子或低碳烷基;R5:低碳烷基;前提是由R1表示的基团的环部分既不是亚甲基也不是其部分饱和基团,且当X为— —或—CO—时,R1不是基。
  • ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME
    申请人:MIYAZAKI Hiroshi
    公开号:US20100249049A1
    公开(公告)日:2010-09-30
    The present invention relates to an arylalkylamine compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, a process for preparing the same, and use of the above-mentioned compound as an activating compound (CaSR agonist) of a Ca sensing receptor, a pharmaceutical composition containing the above-mentioned compound as an effective ingredient, etc. The symbols in the formula represent the following meanings: Ar: optionally substituted aryl or optionally substituted heteroaryl here, the cyclic portion of the heteroaryl is bicyclic heterocyclic ring in which 5- to 6-membered monocyclic heterocyclic ring containing 1 or 2 hetero atom(s) and benzene ring are fused; R 1 : a group selected from the group consisting of optionally substituted cyclic hydrocarbon group, and optionally substituted heterocyclic group; n: an integer of 1 to 3; X: single bonding arm, —CH 2 —, —CO—, —(CH 2 ) m —CO—, —CH(R 2 )—CO—, —(CH 2 ) p —Y—(C(R 3 )(R 4 )) q —CO—, —NH—CO— or —N(R 5 )—CO—; in the above-mentioned respective definitions of the X, the bonding arm described at the left end represents a bond with R 1 ; m is an integer of 1 to 3; p is an integer of 0 to 2; q is an integer of 0 to 2; Y: —O— or —SO 2 —; R 2 : phenyl or lower alkyl; R 3 , R 4 : each independently represents hydrogen atom or lower alkyl; R 5 : lower alkyl; provided that the ring portion of the group represented by R 1 is neither naphthylidine nor partially saturated group thereof, and, when X is —CH 2 — or —CO—, R 1 is not naphthyl.
    本发明涉及一种由下式[I]表示的芳基烷基胺化合物或其药学上可接受的盐,制备该化合物的方法,以及上述化合物作为感受受体(CaSR激动剂)的激活化合物、包含上述化合物作为有效成分的药物组合物等的用途。式中符号表示以下含义:Ar:可选取的取代芳基或可选取的取代杂环芳基,在此,所述杂环的环状部分是由1或2个杂原子的5-6元单环杂环与苯环融合而成的双环杂环;R1:选自可选取的取代环烃基团和可选取的取代杂环基团的群;n:为1至3的整数;X:单键连接臂,-CH2-,-CO-,-( )m-CO-,-CH(R2)-CO-,-( )p-Y-(C(R3)(R4))q-CO-,-NH-CO-或-N(R5)-CO-;在上述X的各自定义中,左端所述连接臂表示与R1的键合;m为1至3的整数;p为0至2的整数;q为0至2的整数;Y:-O-或-SO2-;R2:苯基或低碳烷基;R3,R4:各自独立地表示氢原子或低碳烷基;R5:低碳烷基;所述R1表示的基的环部分既不是亚甲基基团,也不是其部分饱和基团,当X为- -或-CO-时,R1不是基。
  • US8362274B2
    申请人:——
    公开号:US8362274B2
    公开(公告)日:2013-01-29
  • US8486950B2
    申请人:——
    公开号:US8486950B2
    公开(公告)日:2013-07-16
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-(+)-2,2'',6,6''-四甲氧基-4,4''-双(二苯基膦基)-3,3''-联吡啶(1,5-环辛二烯)铑(I)四氟硼酸盐 (R)-N'-亚硝基尼古丁 (R)-DRF053二盐酸盐 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S,2'S)-(-)-[N,N'-双(2-吡啶基甲基]-2,2'-联吡咯烷双(乙腈)铁(II)六氟锑酸盐 (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 (1'R,2'S)-尼古丁1,1'-Di-N-氧化物 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸氯苯那敏-D6 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 韦德伊斯试剂 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非布索坦杂质66 非尼拉朵 非尼拉敏 雷索替丁 阿雷地平 阿瑞洛莫 阿扎那韦中间体 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 镉,二碘四(4-甲基吡啶)- 锌,二溴二[4-吡啶羧硫代酸(2-吡啶基亚甲基)酰肼]-